(NASDAQ: TRDA) Entrada Therapeutics's forecast annual revenue growth rate of -5.5% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.76%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.69%.
Entrada Therapeutics's revenue in 2025 is $61,520,000.On average, 7 Wall Street analysts forecast TRDA's revenue for 2025 to be $1,271,018,779, with the lowest TRDA revenue forecast at $903,502,644, and the highest TRDA revenue forecast at $2,407,811,616. On average, 7 Wall Street analysts forecast TRDA's revenue for 2026 to be $1,311,187,192, with the lowest TRDA revenue forecast at $561,822,710, and the highest TRDA revenue forecast at $2,407,811,616.
In 2027, TRDA is forecast to generate $2,161,641,543 in revenue, with the lowest revenue forecast at $970,080,547 and the highest revenue forecast at $3,411,066,456.